Aprea Therapeutics to Unveil Updated Phase 1 Data for WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR Symposium — Aprea Therapeutics, Inc.

Event summary

Aprea Therapeutics will present updated interim Phase 1 data for its WEE1 inhibitor APR-1051 at the 38th EORTC-NCI-AACR Symposium on November 20, 2026.
The data comes from the ongoing ACESOT-1051 study in patients with advanced solid tumors.
Timothy A. Yap, MBBS, PhD, FRCP from MD Anderson Cancer Center will present the findings.
Aprea's lead programs include APR-1051 and ATRN-119, both in clinical development for solid tumor indications.

The big picture

Aprea Therapeutics' presentation at the EORTC-NCI-AACR Symposium underscores the growing emphasis on precision medicine in oncology. The company's focus on biomarker-defined cancers aligns with broader industry trends toward targeted therapies that minimize toxicity. The success of APR-1051 could position Aprea as a key player in the development of next-generation cancer treatments, particularly for solid tumors.

What we're watching

Clinical Efficacy: How the updated Phase 1 data for APR-1051 will impact investor confidence in its potential as a targeted therapy for advanced solid tumors.
Regulatory Pathway: Whether the interim results will accelerate the regulatory approval process for APR-1051.
Competitive Positioning: The pace at which Aprea can differentiate APR-1051 in a crowded oncology market.